Arbutus Biopharma Corporation
HealthcareNASDAQ:ABUS · NASDAQ Global Select
-$0.03 today
Vol 0.94M · Avg 1.78M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$33.5M +52.1% | -$69.9M +4.0% | -$72.8M -4.9% | -$69.5M +8.9% | -$76.2M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $363.0K -73.7% | $1.4M -1.7% | $1.4M -1.6% | $1.4M -18.6% | $1.8M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 +100.0% | -$8.2M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $7.0M -22.6% | $9.0M -3.4% | $9.3M +29.5% | $7.2M +11.8% | $6.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$10.0M -254.3% | -$2.8M +84.5% | -$18.2M -162.3% | $29.2M +3044.4% | $930.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $1.4M +317.2% | -$633.0K -49.3% | -$424.0K +6.4% | -$453.0K -209.7% | $413.0K | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 +100.0% | -$1.9M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$2.1M | $0 | $0 -100.0% | $5.2M +172.9% | $1.9M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$9.3M -323.2% | -$2.2M +87.7% | -$17.8M -172.7% | $24.5M +4635.0% | $517.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$3.4M -39.0% | -$2.5M +55.6% | -$5.6M -48.2% | -$3.8M -148.2% | $7.8M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$39.6M +38.9% | -$64.8M +24.5% | -$85.9M -143.1% | -$35.4M +47.6% | -$67.5M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | $0 +100.0% | -$182.0K +81.9% | -$1.0M -96.9% | -$512.0K +36.7% | -$809.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 -100.0% | $1.8M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $12.9M +109.1% | -$141.5M -75.8% | -$80.5M +38.3% | -$130.4M -58.6% | -$82.2M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $155.3M -5.7% | $164.6M +24.5% | $132.3M +136.2% | $56.0M -20.4% | $70.3M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$152.6M | $0 -100.0% | $20.0K | $0 +100.0% | -$1.8M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $15.6M -32.1% | $22.9M -54.8% | $50.8M +167.7% | -$74.9M -491.1% | -$12.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $5.7M -87.0% | $44.1M +47.8% | $29.9M +46.9% | $20.3M -84.9% | $134.7M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 +100.0% | -$12.1M | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $7.9M +890.3% | $795.0K -93.1% | $11.5M -21.9% | $14.7M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $5.7M -89.0% | $52.0M +69.7% | $30.6M -3.7% | $31.8M -76.8% | $137.2M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $14.0K +128.6% | -$49.0K -296.0% | $25.0K +213.6% | -$22.0K -540.0% | $5.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$18.3M -282.4% | $10.0M +323.7% | -$4.5M +94.3% | -$78.5M -237.7% | $57.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$39.6M +39.1% | -$65.0M +25.2% | -$86.9M -142.4% | -$35.9M +47.5% | -$68.3M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
GH Research PLC
NASDAQ:GHRS
$1.45B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$969.20M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
ProKidney Corp.
NASDAQ:PROK
$242.99M
SEC Filings
Recent regulatory filings
No filings found.
Does ABUS generate free cash flow?
Arbutus Biopharma Corporation (ABUS) generated -$39,637,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does ABUS produce?
Operating cash flow was -$39,637,000.00, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.